- | Celyad Oncology
Novel CAR T Therapies Help Celyad’s CMO Bring Hope to Fearful Patients
Celyad is focusing on advancing chimeric antigen receptor T cell (CAR T) therapies. “Approved cell therapy products have a very, very high response rate,” he said. “The challenge is in expanding that therapy from hematologic malignancies to other targets – in particular, to solid tumors – where we, as a field, haven’t yet cracked the code.”
- | TFF Pharmaceuticals
Austin-based company developing treatment for lung transplant recipients, COVID survivors
Dale Christensen is the Director of Clinical Development at TFF Pharmaceuticals. It’s an Austin-based company and specializes in “Thin Film Freezing”—a technology first created at UT Austin.
- | Elicio Therapeutic
Lymph node-targeted vaccine elicits COVID-19 protection in vivo
Elicio Therapeutics’ lymph node-targeting vaccine displayed cellular and humoral immunity to SARS-CoV-2 in a pre-clinical study.
- | Scynexis
Scynexis debuts Brexafemme
Scynexis is introducing Brexafemme (ibrexafungerp tablets), the first and only oral non-azole prescription medication approved by the Food and Drug Administration to treat vulvovaginal candidiasis, commonly referred to as vaginal yeast infection.
- | DURECT
PharmaShots Interview: Durect’s James E. Brown Shares Insight on the Data of DUR-928 Presented at EASL 2021
In an interview with PharmaShots, James E. Brown, President, CEO, and Director of Durect shared his views on the clinical data of DUR-928 in P-1b trial for NASH and P-I trial for Hepatic Impairment
- | Aptinyx
Treating the Brain to Address Long-Term Chronic Pain with Andy Kidd MD Aptinyx
Andy Kidd MD is the President and COO and soon to be CEO of Aptinyx. With a focus on Pain Awareness Month, Andy provides a view into the world of treating long-term chronic pain and the necessary innovations to treat the cause of chronic pain in conditions like diabetic peripheral neuropathy and fibromyalgia.
- | Recce Pharmaceuticals
PharmaShots Interview: Recce Pharmaceuticals’ James Graham Shares Insight on the P-I/II Clinical Trial of RECCE 327 (R327) for Infected Burn Wounds
In an interview with PharmaShots, James Graham, CEO of Recce Pharmaceuticals shared his views on the multiple patient dosing in P-I/II clinical trial of RECCE 327 (R327) for the treatment of infected burn wounds.
- | AltruBio
AltruBio snags a CMO after pivot from oncology to immunology
AltruBio has signed a new chief medical officer, five months after a makeover that saw it change its name, its focus and its board.
